Log in
Enquire now
‌

US Patent 10253331 Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine

Patent 10253331 was granted and assigned to Gradalis, Inc. on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Gradalis, Inc.
Gradalis, Inc.
0
Current Assignee
Gradalis, Inc.
Gradalis, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
102533310
Patent Inventor Names
Phillip B. Maples0
Donald Rao0
John J. Nemunaitis0
Neil Senzer0
Date of Patent
April 9, 2019
0
Patent Application Number
156900920
Date Filed
August 29, 2017
0
Patent Primary Examiner
‌
Dana H Shin
0
Patent abstract

Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10253331 Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.